Form 4: Roivant Director Ilan Oren Reports Share Transactions

Roivant Sciences Director Ilan Oren reported the acquisition of 1,164 common shares and the disposition of 124 shares for tax purposes, resulting in a net beneficial ownership of 119,428 shares.

Summary

• Ilan Oren, a Director of Roivant Sciences Ltd. (ROIV), reported transactions involving the company's common shares.
• On January 20, 2026, Oren acquired 1,164 common shares as an award under the Issuer's Non-Employee Director Compensation Plan, fully vested as of the grant date.
• Concurrently, Oren disposed of 124 common shares on January 20, 2026, at a price of $22.98 per share.
• This disposition represents a 'net settlement' by the Issuer to satisfy applicable tax withholding obligations related to the vesting and settlement of the awarded common shares.
• Following these transactions, Ilan Oren beneficially owns 119,428 common shares directly.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to director compensation and tax withholding, which are neutral in sentiment and do not indicate a significant positive or negative shift in company outlook.

Positives

• The acquisition of 1,164 common shares by a director as part of a compensation plan aligns management's interests with those of shareholders.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Ilan Oren, a director of Roivant Sciences Ltd., received an award of 1,164 Common Shares under the Issuer's Non-Employee Director Compensation Plan, which constitutes a transaction between a related party (director) and the company.

Stakeholder Impact

• Minimal impact on shareholders as these are routine compensation and tax-related transactions for a director, reflecting standard corporate governance practices for equity awards.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions for director compensation and tax settlement. It does not provide new information that would significantly alter the investment thesis for Roivant Sciences Ltd. Investors should consider broader company fundamentals and market conditions rather than these standard disclosures.

Keywords

Roivant Sciences, ROIV, Ilan Oren, Form 4, insider transaction, director compensation, share award, tax withholding, beneficial ownership